Drug Shortage Report for GD-ELETRIPTAN
| Report ID | 130219 |
| Drug Identification Number | 02342235 |
| Brand name | GD-ELETRIPTAN |
| Common or Proper name | ELETRIPTAN |
| Company Name | UPJOHN CANADA ULC |
| Market Status | MARKETED |
| Active Ingredient(s) | ELETRIPTAN |
| Strength(s) | 20MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 1x6 |
| ATC code | N02CC |
| ATC description | ANTIMIGRAINE PREPARATIONS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2020-12-21 |
| Actual start date | |
| Estimated end date | |
| Actual end date | 2021-01-11 |
| Shortage status | Resolved |
| Updated date | 2021-01-12 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 17300 TRANS CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-833-287-5646 Email / courriel: UpjohnCanadaCustomerService@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v5 | 2021-01-12 | French | Compare |
| v4 | 2021-01-12 | English | Compare |
| v3 | 2020-12-22 | English | Compare |
| v2 | 2020-12-16 | French | Compare |
| v1 | 2020-12-16 | English | Compare |
Showing 1 to 5 of 5